Breast Cancer Clinical Trials in Nevada

28 recruiting studies across 1 city

Browse by City

All Trials in Nevada

Phase

Trial	Phase	Sponsor	Dist.
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials	N/A	Eastern Cooperative Oncology Group	<1 mi
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	Phase 3	National Cancer Institute (NCI)	<1 mi
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab	Phase 3	Alliance for Clinical Trials in Oncology	<1 mi
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.	Phase 3	Pfizer	<1 mi
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer	Phase 3	NRG Oncology	<1 mi
Mobile Health for Adherence in Breast Cancer Patients	N/A	ECOG-ACRIN Cancer Research Group	<1 mi
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	Phase 2	National Cancer Institute (NCI)	<1 mi
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer	N/A	SWOG Cancer Research Network	<1 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25	Phase 3	NRG Oncology	<1 mi
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)	Phase 3	NRG Oncology	<1 mi
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer	Phase 3	SWOG Cancer Research Network	<1 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection	—	Alliance for Clinical Trials in Oncology	<1 mi
National Cancer Institute "Cancer Moonshot Biobank"	—	National Cancer Institute (NCI)	<1 mi
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics	—	Wake Forest University Health Sciences	<1 mi
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy	Phase 3	AstraZeneca	<1 mi
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)	Phase 3	Gilead Sciences	<1 mi
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)	Phase 3	Merck Sharp & Dohme LLC	<1 mi
A Study of XMT-1660 in Participants With Solid Tumors	Phase 1	Mersana Therapeutics	<1 mi
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer	Phase 3	Canadian Cancer Trials Group	<1 mi
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer	Phase 1	OnKure, Inc.	<1 mi
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)	Phase 3	Merck Sharp & Dohme LLC	<1 mi
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases	Phase 2	Biostar Pharma, Inc.	<1 mi
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer	N/A	Stanford University	<1 mi
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies	Phase 1	Circle Pharma	<1 mi
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors	Phase 1	IDEAYA Biosciences	<1 mi
A Study of Sigvotatug Vedotin in Advanced Solid Tumors	Phase 1	Seagen, a wholly owned subsidiary of Pfizer	<1 mi
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors	Phase 1/2	DualityBio Inc.	<1 mi
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects	Phase 3	Greenwich LifeSciences, Inc.	13 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.